Literature DB >> 25264543

Training the Defense System for Modern-Day Warfare: The Horizons for Immunotherapy and Vaccines for Cancer.

Narendra Kumar1, Jayshree Mishra, Sohel H Quazi.   

Abstract

Entities:  

Year:  2012        PMID： 25264543      PMCID： PMC4175563          DOI： 10.4172/2324-853X.1000e106

Source DB:  PubMed          Journal:  J immunodefic Disord


× No keyword cloud information.
  19 in total

Review 1.  Dendritic cells in cancer immunotherapy.

Authors:  L Fong; E G Engleman
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 3.  [Immunotherapy for cancer--modern immunologic strategies in oncology].

Authors:  N Halama; I Zoernig; D Jäger
Journal:  Dtsch Med Wochenschr       Date:  2008-10-01       Impact factor: 0.628

4.  Molecular mechanism of interleukin-2-induced mucosal homeostasis.

Authors:  Jayshree Mishra; Christopher M Waters; Narendra Kumar
Journal:  Am J Physiol Cell Physiol       Date:  2011-11-23       Impact factor: 4.249

Review 5.  Immune based therapies in cancer.

Authors:  C Krüger; T F Greten; F Korangy
Journal:  Histol Histopathol       Date:  2007-06       Impact factor: 2.303

6.  Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats.

Authors:  Yasuo Iwadate; Makoto Inoue; Takashi Saegusa; Yumiko Tokusumi; Hiroaki Kinoh; Mamoru Hasegawa; Masatoshi Tagawa; Akira Yamaura; Hideaki Shimada
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

Review 7.  Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer.

Authors:  Michael A Morse; Joseph Robert Hall; Janet M D Plate
Journal:  Expert Opin Biol Ther       Date:  2009-03       Impact factor: 4.388

8.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

9.  Janus kinase 3 regulates interleukin 2-induced mucosal wound repair through tyrosine phosphorylation of villin.

Authors:  Narendra Kumar; Jayshree Mishra; Vishal S Narang; Christopher M Waters
Journal:  J Biol Chem       Date:  2007-05-30       Impact factor: 5.157

Review 10.  Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.

Authors:  Simone Mocellin; Donato Nitti
Journal:  Med Res Rev       Date:  2008-05       Impact factor: 12.944
View more
  4 in total

1.  Role of Janus Kinase 3 in Predisposition to Obesity-associated Metabolic Syndrome.

Authors:  Jayshree Mishra; Raj K Verma; Gianfranco Alpini; Fanyin Meng; Narendra Kumar
Journal:  J Biol Chem       Date:  2015-10-08       Impact factor: 5.157

2.  Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.

Authors:  Jayshree Mishra; Randall Simonsen; Narendra Kumar
Journal:  J Biol Chem       Date:  2019-10-25       Impact factor: 5.157

3.  Janus kinase 3 regulates adherens junctions and epithelial mesenchymal transition through β-catenin.

Authors:  Jayshree Mishra; Jugal Kishore Das; Narendra Kumar
Journal:  J Biol Chem       Date:  2017-08-17       Impact factor: 5.157

4.  Mechanistic Role of Jak3 in Obesity-Associated Cognitive Impairments.

Authors:  Premranjan Kumar; Jayshree Mishra; Narendra Kumar
Journal:  Nutrients       Date:  2022-09-09       Impact factor: 6.706
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.